Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide

Simmet,Victor; Noblecourt,Margot; Lizée,Thibaut; Morvant,Benjamin; Girault,Sylvie; Soulié,Patrick; Capitain,Olivier

doi:10.3892/ol.2017.7263

Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide

Authors:
- Victor Simmet
- Margot Noblecourt
- Thibaut Lizée
- Benjamin Morvant
- Sylvie Girault
- Patrick Soulié
- Olivier Capitain
View Affiliations

Affiliations: Department of Medical Oncology, Integrated Center of Oncology (ICO) Paul Papin, Angers 49055, France, Department of Pathologic, Angers University Hospital, Angers 49100, France, Department of Nuclear Medicine, Integrated Center of Oncology (ICO) Paul Papin, Angers 49055, France
Published online on: October 25, 2017 https://doi.org/10.3892/ol.2017.7263
Pages: 48-54
Copyright: © Simmet et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatoid adenocarcinoma (HAC) is a rare and aggressive cancer subtype with a poor prognosis under metastatic conditions. Currently, there is no specific chemotherapy treatment protocol for advanced stages of the disease. This review evaluates two cases of HAC of gastric cardia with synchronous liver metastasis, which were successfully treated by chemotherapy with cisplatin (25 mg/m2 each day) (day 1 to day 3) and etoposide (100 mg/m2) (day 1 to day 3), every three weeks. A structured literary evaluation and reviewed pertinent articles are additionally presented to analyse the different approaches for the treatment of metastatic HAC (mHAC). The two described case reports demonstrated good partial responses to treatment and one of the two patients exhibited a good prognosis after a 9‑year follow‑up. A total of 20 case reports concerning the use of chemotherapy in mHAC were presented in the literature, 11 of which were regarding gastric HACs. The two aforementioned cases result in a total of 22 reports, 11 of which exhibited objective responses to chemotherapy, 8 patients demonstrated a partial response and 3 a complete response. The cisplatin‑based regimen concerned 55% (12/22) patients and enabled 9 (75%) to exhibit a partial or complete response. A total of three patients exhibited a good prognosis in the long‑term follow‑up, all of them treated with a cisplatin‑based regimen. It was demonstrated that the usual digestive regimens were not efficient in the treatment of HAC. In the absence of prospective trials, it may be hypothesized that cisplatin‑based chemotherapy may be the most efficient first‑line treatment in mHAC, with a 75% patient response, in accordance with the literature and follow‑up cases.

View Figures

View References

1	Qu BG, Bi WM, Qu BT, Qu T, Han XH, Wang H, Liu YX and Jia YG: PRISMA-Compliant Article: Clinical characteristics and factors influencing prognosis of patients with hepatoid adenocarcinoma of the stomach in China. Medicine (Baltimore). 95:e33992016. View Article : Google Scholar : PubMed/NCBI
2	Ishikura H, Ishiguro T, Enatsu C, Fujii H, Kakuta Y, Kanda M and Yoshiki T: Hepatoid adenocarcinoma of the renal pelvis producing alpha-fetoprotein of hepatic type and bile pigment. Cancer. 67:3051–3056. 1991. View Article : Google Scholar : PubMed/NCBI
3	Fornasa F: Soft-Tissue Localization of Hepatoid Adenocarcinoma: First case report. Case Rep Oncol. 3:212–217. 2010. View Article : Google Scholar : PubMed/NCBI
4	Yang J, Wang R, Zhang W, Zhuang W, Wang M and Tang C: Clinicopathological and prognostic characteristics of hepatoid adenocarcinoma of the stomach. Gastroenterol Res Pract. 2014:1405872014. View Article : Google Scholar : PubMed/NCBI
5	Nagai E, Ueyama T, Yao T and Tsuneyoshi M: Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis. Cancer. 72:1827–1835. 1993. View Article : Google Scholar : PubMed/NCBI
6	Xiao C, Wu F, Jiang H, Teng L, Song F, Wang Q and Yang H: Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes. Oncol Lett. 10:1605–1609. 2015.PubMed/NCBI
7	Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 339:b27002009. View Article : Google Scholar : PubMed/NCBI
8	Baek SK, Han SW, Oh DY, Im SA, Kim TY and Bang YJ: Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. BMC Gastroenterol. 11:562011. View Article : Google Scholar : PubMed/NCBI
9	Shimada S, Hayashi N, Marutsuka T, Baba Y, Yokoyama S, Iyama K and Ogawa M: Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: Report of two cases. Surg Today. 32:1075–1080. 2002. View Article : Google Scholar : PubMed/NCBI
10	Takeyama H, Sawai H, Wakasugi T, Takahashi H, Matsuo Y, Ochi N, Yasuda A, Sato M, Okada Y, Funahashi H, et al: Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases. World J Surg Oncol. 5:792007. View Article : Google Scholar : PubMed/NCBI
11	Takahashi T, Kochi M, Kanamori N, Kaiga T, Funada T, Fujii M and Takayama T: Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer-report of a case. Gan To Kagaku Ryoho. 36:1885–1888. 2009.(In Japanese). PubMed/NCBI
12	Gavrancic T and Park YH: A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung. J Natl Compr Cancer Netw. 13:387–391. 2015. View Article : Google Scholar
13	Chang YC, Nagasue N, Kohno H, Ohiwa K, Yamanoi A and Nakamura T: Xenotransplantation of alpha-fetoprotein-producing gastric cancers into nude mice. Characteristics and responses to chemotherapy. Cancer. 69:872–877. 1992. View Article : Google Scholar : PubMed/NCBI
14	Metzgeroth G, Ströbel P, Baumbusch T, Reiter A and Hastka J: Hepatoid adenocarcinoma-review of the literature illustrated by a rare case originating in the peritoneal cavity. Onkologie. 33:263–269. 2010. View Article : Google Scholar : PubMed/NCBI
15	Chiba N, Yoshioka T, Sakayori M, Mikami Y, Miyazaki S, Akiyama S, Otsuka K, Yamaura G, Shibata H, Kato S, et al: AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: A case report. Anticancer Res. 25:2965–2968. 2005.PubMed/NCBI
16	Lin CW, Hsu CC, Chang HC, Sun YC, Sun PL, Hsu CY and Perng DS: Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: A case report. Cases J. 2:63172009.PubMed/NCBI
17	Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V, Menarguez-Pina F, Ruiz-Maciá JA and Morcillo MA: Hepatoid adenocarcinoma of the stomach-a different histology for not so different gastric adenocarcinoma: A case report. Int Semin Surg Oncol. 6:132009. View Article : Google Scholar : PubMed/NCBI
18	Cappetta A, Bergamo F, Mescoli C, Lonardi S, Rugge M and Zagonel V: Hepatoid adenocarcinoma of the colon: What should we target? Pathol Oncol Res. 18:93–96. 2012. View Article : Google Scholar : PubMed/NCBI
19	Ye MF, Tao F, Liu F and Sun AJ: Hepatoid adenocarcinoma of the stomach: A report of three cases. World J Gastroenterol. 19:4437–4442. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ahn JS, Jeon JR, Yoo HS, Park TK, Park CK, Sinn DH and Paik SW: Hepatoid adenocarcinoma of the stomach: An unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma. Clin Mol Hepatol. 19:173–178. 2013. View Article : Google Scholar : PubMed/NCBI
21	Majumder S and Dasanu CA: Hepatoid variant of pancreatic cancer: Insights from a case and literature review. JOP. 14:442–445. 2013.PubMed/NCBI
22	Nagai Y, Kato T, Harano M, Satoh D, Choda Y, Tokumoto N, Kanazawa T, Matsukawa H, Ojima Y, Idani H, et al: A case of AFP-producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy. Gan To Kagaku Ryoho. 41:2349–2351. 2014.(In Japanese). PubMed/NCBI
23	Chen Y, Schaeffer DF and Yoshida EM: Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease. World J Gastroenterol. 20:12657–12661. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hu CH, Li QL, Li HP, Fan SQ, Zhang HX, Liu XL, He Y, Huang M, Lu M, Wang SS and Wu F: Rare coexistence of mediastinal hepatoid adenocarcinoma, idiopathic azoospermia and horseshoe kidney: A case report and review of the literature. Int J Clin Exp Pathol. 8:11741–11746. 2015.PubMed/NCBI
25	Karayiannakis AJ, Kakolyris S, Giatromanolaki A, Courcoutsakis N, Bolanaki H, Chelis L, Sivridis E and Simopoulos C: Hepatoid Adenocarcinoma of the Gallbladder: Case Report and Literature Review. J Gastrointest Cancer. 43:139–144. 2012. View Article : Google Scholar
26	Petrelli F, Ghilardi M, Colombo S, Stringhi E, Barbara C, Cabiddu M, Elia S, Corti D and Barni S: A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib. J Gastrointest Cancer. 43:97–102. 2012. View Article : Google Scholar : PubMed/NCBI
27	Mokrim M, Belbaraka R, Allaoui M, Kairaouani M, Mahassini N, Tahri A and Errihani H: Hepatoid Adenocarcinoma of the Lung: A Case Report and Literature Review. J Gastrointest Cancer. 43:125–127. 2012. View Article : Google Scholar